Guerbet: Additional information related to 2021 financial outlook
March 29 2021 - 2:25AM
Guerbet: Additional information related to 2021 financial outlook
Additional information related to 2021
financial outlook
Villepinte, March 29, 2021 –
Guerbet (FR0000032526), a global specialist in contrast
agents and solutions for medical imaging, is detailing information
related to 2021 outlook disclosed in the March 24th, 2021 press
release entitled “2020 Annual Results”.
In terms of profitability, the company is
targeting the following EBITDA trends:
- Short term, a growing EBITDA in 2021, with a minimum rate
EBITDA/SALES equal to 2020 (14.1%)
- Medium term, an improving EBITDA/SALES rate, ensuring strong,
lasting growth for the Group
A detailed presentation of 2020 Annual Results
is available under Investor Relation headings, on Guerbet’s site
https://www.guerbet.com/investors/.
Upcoming events:
Reporting of Q1 2021 revenue
April 22, 2021, after
trading
About Guerbet
Guerbet is a leader in medical imaging
worldwide, offering a comprehensive range of pharmaceutical
products, medical devices, and digital and AI solutions for
diagnostic and interventional imaging to improve patient diagnosis
and treatment. A pioneer in contrast media for 95 years, with more
than 2,600 employees worldwide, Guerbet continuously innovates and
devotes 10% of its sales to research and development in four
centers in France, Israel, and the United States. Guerbet (GBT) is
listed on Euronext Paris (segment B – mid caps) and generated
€712 million in revenue in 2020. For more information about
Guerbet, please visit www.guerbet.com.
Forward-looking statements
Certain information contained in this press
release does not reflect historical data but constitutes
forward-looking statements. These forward-looking statements are
based on estimates, forecasts, and assumptions, including but not
limited to assumptions about the current and future strategy of the
Group and the economic environment in which the Group operates.
They involve known and unknown risks, uncertainties, and other
factors that may result in a significant difference between the
Group's actual performance and results and those presented
explicitly or implicitly by these forward-looking statements.
These forward-looking statements are valid only
as of the date of this press release, and the Group expressly
disclaims any obligation or commitment to publish an update or
revision of the forward-looking statements contained in this press
release to reflect changes in their underlying assumptions, events,
conditions, or circumstances. The forward-looking statements
contained in this press release are for illustrative purposes only.
Forward-looking statements and information are not guarantees of
future performance and are subject to risks and uncertainties that
are difficult to predict and are generally beyond the Group's
control. These risks and uncertainties include but are not limited
to the uncertainties inherent in research and development, future
clinical data and analyses (including after a marketing
authorization is granted), decisions by regulatory authorities
(such as the US Food and Drug Administration or the European
Medicines Agency) regarding whether and when to approve any
application for a drug, process, or biological product filed for
any such product candidates, as well as their decisions regarding
labeling and other factors that may affect the availability or
commercial potential of such product candidates. A detailed
description of the risks and uncertainties related to the Group's
activities can be found in Chapter 4.8 "Management and risk
factors" of the Group's Universal Registration Document filed with
the AMF (French financial markets authority) under
number D-20-0369 on April 28, 2020, available on the Group's
website (www.guerbet.com).
For more information about Guerbet, please visit
www.guerbet.com
Contacts
Jérôme
Estampes Chief Financial Officer 01 45 91 50 00
|
Financial
Communications Benjamin Lehari 01 56 88 11 25
blehari@actifin.fr Press Jennifer Jullia 01
56 88 11 19 jjullia@actifin.fr |
- CP_Précision guidance2021_VAnglais
Guerbet (EU:GBT)
Historical Stock Chart
From Sep 2024 to Oct 2024
Guerbet (EU:GBT)
Historical Stock Chart
From Oct 2023 to Oct 2024